Skip to content

A 5 Year Clinical Investigation on Creos Xenoprotect

A 5 Year Clinical Investigation on Creos Xenoprotect

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02373787
Acronym
CXP
Enrollment
49
Registered
2015-02-27
Start date
2013-07-31
Completion date
2017-10-02
Last updated
2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Implant

Keywords

Resorbable, Collagen membrane, NobelReplace CC

Brief summary

A 5-year clinical investigation on creos xenoprotect

Detailed description

Randomized, prospective, multi-center study evaluating creos xenoprotect versus Bio-Gide® for guided bone regeneration in dehiscence defects

Interventions

DEVICEcreos xenoprotect

Implant placement with simultaneous bone augmentation

DEVICEBio-Gide

resorbable collagen membrane

Sponsors

Nobel Biocare
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Obtained informed consent from the subject. * The subject shall be at least 18 years of age and has passed cessation of growth. * The subject must be in such a physical and mental condition that a 5-year follow-up period can be carried out without foreseeable problems. * The patient is willing and able to comply with all study related procedures (such as exercising oral hygiene and attending all follow-up procedures). * The subject requires a single unit implant restoration with guided bone regeneration in bony defects in the anterior and premolar areas of maxilla or mandible. * If two or more site single unit implant restorations requiring bone augmentation are required, only one will be included in the study, the other site will be treated with standard of care. * The subject shall be healthy and compliant with good oral hygiene. * Full-mouth bleeding score (FMBS) lower than 25% \[20\]. * Full-mouth plaque score (FMPI) lower than 20% \[21\]. * The implant site is free from infection and extraction remnants. * The subject shall have a favourable and stable occlusal relationship. * Natural roots are adjacent to implant site. * The subject is suitable for a 2-stage surgical procedure. Secondary inclusion criteria at time of surgery * Sufficient bone volume at the implant site for placing a NobelReplace CC implant. * Initial implant stability as assessed by hand testing. * Defect size for guided bone regeneration: Height ≥ 3 mm and ≤ 7 mm as assessed with a UNC15 periodontal probe.

Exclusion criteria

* Previous bone augmentation at the implant site. * Extraction site less than 3 months after extraction. * Soft tissue grafting at implant placement, soft tissue grafting is allowed only at re-entry. * Health conditions, which do not permit the surgical treatment. * Any disorders in the planned implant area such as previous tumours, chronic bone disease or previous irradiation * Infections in the planned implantation site or adjacent tissue. * Acute, untreated periodontitis in the planned implantation site or adjacent tissue. * Any ongoing application of interfering medication (steroid therapy, bisphosphonate, etc). * Alcohol or substance abuse as noted in subject records or in subject history. * Heavy smoking (\>10 cigarettes/day). * Uncontrolled diabetes, i.e. a subject with diagnosed diabetes that has a history of neglecting doctor's recommendations regarding treatment, food and alcohol intake or A1c level above 8%. * Severe bruxism or other destructive habits. * Pregnant or lactating women at the time of collagen membrane insertion.

Design outcomes

Primary

MeasureTime frame
To demonstrate bone regeneration through measurement of defect height6 months

Secondary

MeasureTime frame
Adverse events (AEs)6 months

Other

MeasureTime frame
Membrane Dehiscence6 months
success and survival rates of implants5 years

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026